WASHINGTON, DC — For patients with acute-on-chronic liver failure (ACLF) undergoing modest-volume paracentesis for ascites, oral midodrine may be an alternative to intravenous albumin for ...

Midodrine, 2-amino- N - (2- (2,5-dimethoxy-phenyl)-2-hydroxyethyl), is an α 1 -adrenergic receptor agonist prodrug of desglymidodrine. 6 Midodrine is a well-absorbed (93%) drug and compared with ...

Midodrine, when administered in tandem with guidance on lifestyle risk reduction, lowered the recurrence of vasovagal syncope among patients who experienced fainting spells, data show. “This is ...

Treatment with midodrine and albumin mildly suppressed the activity of vasoconstrictor systems in patients with cirrhosis waiting for liver transplantation but did not significantly prevent ...

Taking midodrine can reduce vasovagal syncope in younger healthy patients, according to a new study. The randomized, placebo-controlled, double-blind trial included 133 patients with recurrent ...

Efficacy of midodrine vs placebo in neurogenic orthostatic hypo-tension. A randomized, double-blind multicenter study. Midodrine Study Group. JAMA. 1997;277 (13):1046-1051. 70.

The FDA has issued a Proposal to Withdraw Marketing Approval for ProAmatine (midodrine HCl, from Shire), used in the treatment of orthostatic hypotension, because required post-approval studies ...

Droxidopa had a significantly longer median persistence than midodrine (240 days; 95% CI, 210-299 vs 180 days; 95% CI, 160-183; P <.0001).

In the midodrine group, 3 people dropped out because of pilomotor reactions, 7 for urinary urgency or retention, 5 for supine hypertension, and 8 for other reasons. In Jankovic et al. (1993), 5/74 ...

Midodrine was approved in the United States by the Food and Drug Administration (FDA) in 1996 for the treatment of orthostatic hypotension.

Product overview Midodrine (Bramox, Brancaster Pharma Limited) received a marketing authorisation in March 2015 and was launched in the UK in July 2015. It is licensed for treating adults with severe ...